Cargando…

Therapy-related myeloid leukemia during erlotinib treatment in a non-small cell lung cancer patient: A case report

BACKGROUND: Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are tolerable drugs used for patients with EGFR-mutant advanced non-small cell lung cancer (NSCLC). Serious adverse reactions are uncommon compared with cytotoxic drugs. CASE SUMMARY: A 52-year-old man presented with...

Descripción completa

Detalles Bibliográficos
Autores principales:	Koo, So-My, Kim, Ki-Up, Kim, Yang-Ki, Uh, Soo-Taek
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Baishideng Publishing Group Inc 2021
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8409203/ https://www.ncbi.nlm.nih.gov/pubmed/34540979 http://dx.doi.org/10.12998/wjcc.v9.i24.7205

Ejemplares similares

Effect of Rivaroxaban on Fibrinolytic Therapy in Massive Pulmonary Embolism: Two Cases
por: Kim, Hye-Jin, et al.
Publicado: (2014)

p53 Expression in a Malignant Mesothelioma Patient during Seven-Year Follow-up
por: Koo, So-My, et al.
Publicado: (2014)

The Perioperative Management of Antithrombotic Therapies Using Enoxaparin
por: Hwang, Hun-Gyu, et al.
Publicado: (2017)

Incidence and Risk Factors of Pneumonia in Hospitalized Patients with Seasonal Influenza A or B
por: Chu, Seongjun, et al.
Publicado: (2017)

Clinical Experiences of High-Risk Pulmonary Thromboembolism Receiving Extracorporeal Membrane Oxygenation in Single Institution
por: Jang, Joonyong, et al.
Publicado: (2022)

Treatment of connective tissue disease-associated interstitial lung disease: the pulmonologist’s point of view
por: Koo, So-My, et al.
Publicado: (2017)

Different Responses to Clarithromycin in Patients with Cryptogenic Organizing Pneumonia
por: Oh, Ji Hyun, et al.
Publicado: (2015)

Inhibition of Vitamin D Receptor Translocation by Cigarette Smoking Extracts
por: Uh, Soo-Taek, et al.
Publicado: (2012)

Increased antioxidant activity after exposure of ozone in murine asthma model
por: Kim, Yang Ki, et al.
Publicado: (2017)

Proteomic differences with and without ozone-exposure in a smoking-induced emphysema lung model
por: Uh, Soo-Taek, et al.
Publicado: (2015)

The activation of NLRP3-inflammsome by stimulation of diesel exhaust particles in lung tissues from emphysema model and RAW 264.7 cell line
por: Uh, Soo-Taek, et al.
Publicado: (2017)

Cigarette Smoking-Induced Acute Eosinophilic Pneumonia: A Case Report Including a Provocation Test
por: Bok, Gene Hyun, et al.
Publicado: (2008)

Bowel Perforation after Erlotinib Treatment in a Patient with Non-Small Cell Lung Cancer
por: Cheon, Yun-Hong, et al.
Publicado: (2011)

A comparative study on erlotinib & gefitinib therapy in non-small cell lung carcinoma patients
por: Thomas, Preenumol, et al.
Publicado: (2019)

Engineering of Amphiphilic Erlotinib Analogue as Novel Nanomedicine for Non-Small Cell Lung Cancer Therapy
por: Cong, Mei, et al.
Publicado: (2023)

Identifying erlotinib-sensitive non-small cell lung carcinoma tumors in mice using [(11)C]erlotinib PET
por: Abourbeh, Galith, et al.
Publicado: (2015)

Review of erlotinib in the treatment of advanced non-small cell lung cancer
por: Ganjoo, Kristen N, et al.
Publicado: (2007)

Comparison of Plasma Metabolites From Patients With Non-Small Cell Lung Cancer by Erlotinib Treatment and Skin Rash
por: Lee, Won Kil, et al.
Publicado: (2023)

A randomized Phase 2 study to compare erlotinib with or without bevacizumab in previously untreated patients with advanced non–small cell lung cancer with EGFR mutation
por: Lee, Youngjoo, et al.
Publicado: (2022)

Efficacy and Safety of Afatinib for EGFR-mutant Non-small Cell Lung Cancer, Compared with Gefitinib or Erlotinib
por: Kim, Youjin, et al.
Publicado: (2019)

The Frequency of EGFR and KRAS Mutations in the Turkish Population with Non-small Cell Lung Cancer and their Response to Erlotinib Therapy
por: Demiray, A, et al.
Publicado: (2018)

Adding Erlotinib to Chemoradiation Improves Overall Survival but not Progression-Free Survival in Stage III Non-Small-Cell Lung Cancer
por: Komaki, Ritsuko, et al.
Publicado: (2015)

Response to gefitinib and erlotinib in Non-small cell lung cancer: a retrospective study
por: Emery, Ivette F, et al.
Publicado: (2009)

Observational study on the efficacy and safety of erlotinib in patients with non-small cell lung cancer
por: KABURAGI, TAKAYUKI, et al.
Publicado: (2013)

Docetaxel-carboplatin in combination with erlotinib and/or bevacizumab in patients with non-small cell lung cancer
por: Boutsikou, Eftimia, et al.
Publicado: (2013)

Role of erlotinib in the targeted treatment of non-small-cell lung cancer in Chinese patients
por: Li, Wei, et al.
Publicado: (2014)

Adherence, exposure and patients’ experiences with the use of erlotinib in non-small cell lung cancer
por: Timmers, Lonneke, et al.
Publicado: (2015)

YAP promotes erlotinib resistance in human non-small cell lung cancer cells
por: Hsu, Ping-Chih, et al.
Publicado: (2016)

EGFR testing and erlotinib use in non-small cell lung cancer patients in Kentucky
por: Larson, Kara L., et al.
Publicado: (2020)

Identification of microRNAs that promote erlotinib resistance in non-small cell lung cancer
por: Pal, A.S., et al.
Publicado: (2020)

New Targeted Therapy for Non-Small Cell Lung Cancer
por: Chung, Eun Ki, et al.
Publicado: (2023)

Therapy‐related acute myeloid leukemia after chemotherapy in extensive disease‐small cell lung cancer
por: Ueda, Naoko, et al.
Publicado: (2018)

Clinical efficacy of erlotinib, a salvage treatment for non-small cell lung cancer patients following gefitinib failure
por: Cho, Kyoung Min, et al.
Publicado: (2015)

Gefitinib or Erlotinib as Maintenance Therapy in Patients with Advanced Stage Non-Small Cell Lung Cancer: A Systematic Review
por: Chen, Xiaofeng, et al.
Publicado: (2013)

Second- and Further-Line Therapy with Erlotinib in Patients with Advanced Non-Small-Cell Lung Cancer in Daily Clinical Practice
por: Krainhöfer, Josephine, et al.
Publicado: (2014)

Efficacy and dose of afatinib in patients with non‐small cell lung cancer after failure of prior gefitinib or erlotinib treatment
por: Choi, Hayoung, et al.
Publicado: (2021)

Erlotinib-Associated Rash in Advanced Non-Small Cell Lung Cancer: Relation to Clinicopathological Characteristics, Treatment Response, and Survival
por: Kainis, Ilias, et al.
Publicado: (2018)

DNA Polymerase Alpha Subunit B Is a Binding Protein for Erlotinib Resistance in Non-Small Cell Lung Cancer
por: Kim, Tae Young, et al.
Publicado: (2020)

Role of erlotinib in first-line and maintenance treatment of advanced non-small-cell lung cancer
por: Reguart, Noemí, et al.
Publicado: (2010)

EGFR Exon-Level Biomarkers of the Response to Bevacizumab/Erlotinib in Non-Small Cell Lung Cancer
por: Baty, Florent, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_obrgr428bur85hdvf2k16q904l